Real-World Experience of Pidotimod in Mexican Pediatric Patients

Introduction: Pidotimod is an immunostimulant molecule widely used to treat respiratory tract infections (RTIs) in children. It may also be useful for the treatment of allergic respiratory diseases. This real-world study evaluated the incidence of recurrent RTI after treatment with pidotimod in children with acute RTI or allergic disease in Mexico. Methods: This observational, cross-sectional, retrospective, two-center study included medical records of children with active RTI or risk of recurrent RTI who were prescribed pidotimod for acute/subacute or chronic respiratory disease in two private clinics in Mexico City. Results: Fifty children were included, (n=27, 54%) were girls, (n=39, 78%) were between 2 and 11 years of age and (n=10, 20%) were less than 2 years old, with a duration of follow-up that ranged between 11 and 384 days. The majority (n=36, 72%) received Pidotimod for both acute illness and prophylactic continuation; four children received Pidotimod only prophylactically. Forty children (80%) were prescribed Pidotimod for recurrent infection. The number of respiratory episodes decreased from 50 (100%) to 2 (4%), demonstrating an efficacy of 96%. Of the total patients treated with Pidotimod, 96% did not experience another infection during the follow-up period. No adverse events of Pidotimod were reported and almost all (n = 49, 98%) of the children found the taste of Pidotimod acceptable. Conclusions: Pidotimod demonstrated 96% efficacy in recurrent respiratory infections and was well tolerated, supporting its continued use for the treatment of pediatric respiratory conditions, including recurrent RTIs and allergic diseases.